Novavax Inc vs Advanced Drainage Systems Inc — how do they compare? Novavax Inc trades at $7.95 (market cap $1.31B), while Advanced Drainage Systems Inc trades at $139.31 (market cap $10.83B). The key difference: Advanced Drainage Systems Inc is far larger — about 8.3× Novavax Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WMS | |
|---|---|---|
Market Cap | $1.31B | $10.83B |
Sector | Health | Industrials |
52-Week High | $11.19 | $175.38 |
52-Week Low | $6.22 | $129.50 |
Enterprise Value | $889.30M | $12.44B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Advanced Drainage Systems (WMS) trades at $141.67, down 1.58% with bearish technical signals. The company demonstrates strong profitability with 14% net margins and consistent earnings beats, though revenue growth has moderated. Recent Q1 2027 results showed 21% sales growth to $1 billion, beating expectations. Technical indicators show resistance at $143 with support at $140, while moving averages signal bearish momentum.
WMS offers solid fundamentals with attractive upside to the $185.86 consensus target, but faces near-term technical headwinds. The company's water management solutions benefit from infrastructure spending, though competitive pressures and margin compression present risks. Analyst sentiment is mixed with 41% buy ratings, suggesting cautious optimism for long-term investors.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →